Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Subscribe To Our Newsletter & Stay Updated